Reduced tissue ornithine increases the cytotoxicity of difluoromethylornithine

Anticancer Research

Volumn 16, Issue 6 B, 1996, Pages 3731-3736

  Bruce Grossie Jr , V ^a,b   Nishioka, Kenji ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Difluoromethylornithine; Ornithine; Parenteral nutrition

Indexed keywords

AMINO ACID; EFLORNITHINE; ESSENTIAL AMINO ACID; NITROGEN; ORNITHINE; POLYAMINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER TRANSPLANTATION; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CYTOTOXICITY; DRUG LIVER LEVEL; DRUG TISSUE LEVEL; DRUG TUMOR LEVEL; INTRAVENOUS DRUG ADMINISTRATION; MALE; NONHUMAN; POLYAMINE METABOLISM; POLYAMINE SYNTHESIS; PRIORITY JOURNAL; RAT; SARCOMA; SPLEEN; THROMBOCYTOPENIA; TISSUE LEVEL; TOTAL PARENTERAL NUTRITION; TUMOR GROWTH;

AMINO ACIDS, ESSENTIAL; ANIMALS; ANTINEOPLASTIC AGENTS; EFLORNITHINE; LIVER; MALE; ORNITHINE; PARENTERAL NUTRITION, TOTAL; POLYAMINES; RATS; RATS, INBRED F344; SARCOMA, EXPERIMENTAL; SPLEEN; WEIGHT LOSS;

EID: 0030513877     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Pegg AE and McCann PP: Polyamine metabolism and function. Am J Physiol 243: C212-C221, 1987.
2. Pegg AE: Recent advances in the biochemistry of polyamines in eukaryotes. Biochem J 234: 249-262, 1986.
3. Tabor CW and Tabor H: Polyamines. Ann Rev Biochem 53: 749-790, 1984.
4. Pegg AE: Polyamine metabolism and its importance in neoplastic growth and as a target for chemotherapy. Cancer Res 48: 759-774, 1988.
5. Hirvonen A, Eloranta T, Hwonen, Alhonen L, Janne J: Characterization of difluoromethyloqnithine-resistant mouse and human tumour cell lines. Biochem J 258: 709-713, 1989.
6. Grossie VB, Jr, Ota DM, Ajani JA, Chang T-H, Patenia D and Nishioka K: Reduction of difluoromethylornithine-induced thrombocytopenia with ornithine while maintaining antitumor activity. Cancer Res 49: 4159-4162, 1989.
7. Grossie VB, Jr, Ajani JA, Nishioka K: Effect of intravenous α - difluoromethylornithine on the polyamine levels of normal tissue and a transplantable fibrosarcoma. Cancer Res 47: 1836-1840, 1987.
8. Ajani JA, Ota D M, Grossie VB, Jr, Abbruzzese JL, Faintuck JS, et al: Evaluation of continuous-infusion of alpha-difluoromethylornithine therapy in colorectal carcinoma CancerChemPharmacol 26: 221-226, 1990.
9. Ota DM, Grossie VB, Jr, Ajani JA, Stephans LC, and Nishioka K: Red blood cell polyamine levels and host toxicity during continuous alpha-difluoromethylornithine infusion. Int J Cancer 38: 245-249, 1986.
10. Nishioka K, Grossie VB, Jr, Ajani JA, Patenia D, Chan T-H, and Ota DM: Polyaminedirected preferential nutritional repletion of normal tissues in tumor-bearing hosts. Int J Cancer 42: 744-747, 1988.
11. Steiger E, Vars HM, and Dudrick SJ: A technique for long term intravenous feeding in unrestrained rats. Arch Surg 104: 330-332, 1972.
12. Kimura H, Finch CA, and Adamson JM: Hematopoiesis in the rat: Quantitation of hematopoietic progenitors and the response to iron-deficiency anemia. J Cell Physiol 726: 298-306, 1986.
13. Grossie B, Ajani J, Ota D, and Nishioka K: Tumor growth recovery after antitumor drug treatment is delayed by difluoromethylornithine. Proc Amer Assoc Cancer Res 33: A2517, 1992.